Effect of Galantamine on Inflammation and Cognition
Status:
Active, not recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
This study tests whether galantamine (GAL) reduces HIV-related inflammation and cognitive
deficits. In this double-blind placebo-controlled crossover study, HIV-infected individuals
(N=120; 60 smokers and 60 non-smokers) will be randomized to 12 weeks of GAL or placebo,
followed by a 4-week washout, then 12 weeks of GAL or placebo (arms switched). Outcomes are
monocyte/macrophage and T cell activation and neurocognitive performance.